1. Home
  2. KN vs PHVS Comparison

KN vs PHVS Comparison

Compare KN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

N/A

Current Price

$37.57

Market Cap

2.8B

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$31.49

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KN
PHVS
Founded
1946
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.4B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
KN
PHVS
Price
$37.57
$31.49
Analyst Decision
Buy
Strong Buy
Analyst Count
4
14
Target Price
$43.75
★ $57.49
AVG Volume (30 Days)
567.0K
★ 788.3K
Earning Date
10-22-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 118.94
N/A
EPS
★ 0.11
N/A
Revenue
★ $593,200,000.00
N/A
Revenue This Year
$12.37
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
$337.64
★ N/A
Revenue Growth
★ 7.17
N/A
52 Week Low
$20.57
$20.65
52 Week High
$42.93
$43.25

Technical Indicators

Market Signals
Indicator
KN
PHVS
Relative Strength Index (RSI) 52.81 38.06
Support Level $33.56 $24.95
Resistance Level $40.08 $36.36
Average True Range (ATR) 1.02 1.29
MACD 0.03 -0.17
Stochastic Oscillator 39.82 22.06

Price Performance

Historical Comparison
KN
PHVS

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: